(+44)113 343 8639
Summary: I am a clinician, and I lead the LICAP Molecular Haematopathology group.
Teaching Commitments: Lectures –Molecular Medicine MSc
Dr Reuben Tooze's research interests are in studying the factors controlling B-cell terminal differentiation and plasma cell survival, and the relationship of these processes to lymphoma and myeloma.
Dr Tooze graduated from St Bartholomews Hospital Medical School (University of London) in 1992. He began his histopathology training at Addenbrookes Hospital Cambridge in 1993, and remained in Cambridge as a Wellcome Trust Clinical Training Fellow from 1994-1997, studying for a PhD in Immunology under Prof Douglas Fearon. During this time he met and published with his wife and co-investigator Dr Gina Doody. Following his PhD he remained based in Cambridge as a Specialist Registrar in Histopathology. During this time he completed much of his general histopathology training but retained an active research interest providing comparative pathology support in relation to knockout, transgenic and inbred murine and rat disease models.
Throughout his clinical training Dr Tooze developed a special interest in lymphoma pathology. In 2000 Dr Tooze took up a CRUK Specialist Registrar post in Leeds. Following completion of MRCPath (histopathology) Dr Tooze committed exclusively to haematopathology working initially as a registrar and subsequently as an honorary consultant at the Haematological Malignancy Diagnostic Service of the Leeds Teaching Hospitals NHS Trust. Dr Tooze continues to work actively as an honorary consultant in diagnostic haematopathology.
Dr Tooze was awarded an MRC Clinical Fellowship in 2003, and in collaboration with Dr Doody developed an independent research program focusing on the function and regulation of BLIMP1/PRDM1, the transcriptional master regulator of plasma cell differentiation.
This MRC Fellowship was followed in 2008 by award of a CRUK Senior Clinical Fellowship aimed at understanding the transcriptional complexity of terminal B-cell differentiation and its relationship to lymphoma. During this fellowship the lab has developed the first system allowing the in vitro generation and maintenance of long-lived human plasma cells, established the genome wide relationship of several transcription factors, developed a real-time gene expression classifier for the classification of diffuse large B-cell lymphoma currently underpinning a phase 3 clinical trial and performed the first meta-analysis of gene expression in this lymphoma type.